Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide. by Arpel, Alexia (author) et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Inhibition of primary breast tumor growth and metastasis using 
a neuropilin-1 transmembrane domain interfering peptide
Alexia Arpel1,2, Coralie Gamper1, Caroline Spenlé1, Aurore Fernandez1, Laurent 
Jacob1, Nadège Baumlin1, Patrice Laquerriere2, Gertraud Orend1, Gérard Crémel1, 
Dominique Bagnard1
1INSERM U 1109, MN3T Lab, Labex Medalis, Strasbourg University, Strasbourg, France
2CNRS UMR 7178, Institut Pluridisciplinaire Hubert Curien, Strasbourg University, Strasbourg, France
Correspondence to: Dominique Bagnard, email: bagnard@unistra.fr
Keywords: neuropilin-1, breast cancer, metastasis, treatment, peptidea
Received: September 28, 2015    Accepted: May 28, 2016    Published:
ABSTRACT
The transmembrane domains (TMD) in membrane receptors play a key role in 
cell signaling. As previously shown by us a peptide targeting the TMD of neuropilin-1 
(MTP-NRP1), blocks cell proliferation, cell migration and angiogenesis in vitro, and 
decreases glioblastoma growth in vivo. We now explored the clinical potential of MTP-
NRP1 on breast cancer models and demonstrate that MTP-NRP1 blocks proliferation of 
several breast cancer lines including the MDA-MB-231, a triple negative human breast 
cancer cell line. In models with long term in vivo administration of the peptide, MTP-
NRP1 not only reduced tumor volume but also decreased number and size of breast 
cancer metastases. Strikingly, treating mice before tumors developed protected from 
metastasis establishment/formation. Overall, our results report that targeting the 
TMD of NRP1 in breast cancer is a potent new strategy to fight against breast cancer 
and related metastasis.
INTRODUCTION
In spite of broad achievements in early breast 
cancer diagnosis, death due to breast cancer and related 
metastases remains a sobering fact [1, 2]. This indicates 
the need to develop new strategies and therapeutic tools 
with effective anti-metastatic properties. To address this 
need, we tested a novel strategy inhibiting the recently 
identified breast cancer target neuropilin-1 (NRP1), 
a membrane receptor involved in nervous system 
development and angiogenesis [3]. Mounting evidence 
now indicates a crucial role in breast cancer tumorigenesis 
and metastasis. NRP1 promotes breast cancer cell survival 
[4, 5] and different studies showed a role in cell migration 
and metastasis [6–8]. Consistently, the expression of 
NRP1 in human breast cancer tissue [7, 9, 10] negatively 
correlates with patient survival [7, 9]. Barr and co-workers 
demonstrated in 2005 [11] that a peptide targeting the 
VEGF165-binding site of NRP1, antagonises the autocrine 
anti-apoptotic effects of VEGF in cultured 4T1 and MDA-
MB-231 breast carcinoma cells. Moreover, the group 
of Perret and colleagues described that a heptapeptide 
also inhibiting VEGF binding to NRP1 reduced tumor 
volume, blood vessel density in orthotopic mammary 
MDA-MB-231 tumors [12]. We had previously identified 
a peptide that antagonizes activities of the transmembrane 
domain in NRP1 (Membrane Targeting Peptide NRP1, 
MTP-NRP1). This peptide exhibited in vitro and in vivo 
anti-proliferative, anti-migratory and anti-angiogenic 
properties [13, 14] blocking glioblastoma growth. In the 
present study, we decided to explore whether targeting 
NRP1 with our peptide potentially is also suitable for 
blocking breast cancer growth and metastasis. Because 
of the lack of targeted therapy for triple negative breast 
cancer, we focused our study on the aggressive human 
breast cancer line MDA-MB-231 (Estrogen Receptor 
ER-, Progesterone receptor PR-, HER2-) recapitulating 
this unfavorable clinical context. We found that long 
term tri-weekly intraperitoneal administration of MTP-
NRP1 significantly improved the overall survival of mice 
compared to vehicle-treated controls. This benefit could be 
attributed to reduced primary tumor growth as assessed by 
bioluminescence in vivo imaging and the RECIST criteria 
[15, 16]. We also report an anti-metastatic effect of MTP-
NRP1 preventing establishment and growth of metastases. 
Hence, we provide data demonstrating the protective effect 
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of MTP-NRP1 as it reduced metastasis formation and 
growth when administrated before grafting of tumor cells. 
Overall, our data not only validate the use of peptides 
antagonizing NRP1 as very powerful approach to fight 
triple negative breast cancer growth and metastasis, but 
also exemplify that drugs targeting the TMD of membrane 
receptors offer a convincing alternative to conventional 
drugs targeting extra- or intracellular domains.
RESULTS
MTP-NRP1 inhibits proliferation of 4T1 murine 
breast cancer cells
The transmembrane domain of NRP1 is 100% 
conserved across mammalian species thereby simplifying 
preclinical validation. To address the biological activity of 
MTP-NRP1 in breast cancer we first focused on a murine 
setting to evaluate the peptide in an immunocompetent 
mouse model. To this end, we performed a proliferation 
MTT assay on murine 4T1 cells expressing NRP1 
(Figure 1A). We found a significant dose-dependent 
reduction of cell proliferation starting at a concentration 
of the peptide of 10-8M exhibiting a maximal effect at 10-6 
M. We then produced subcutaneous tumors in Balb/C mice 
by grafting 4T1 cells. MTP-NRP1 was administrated for 
a period of three weeks every three days (1 μg/kg) when 
tumors reached a volume of 200 mm3. As seen in Figure 
1C, the tumor size was 67% reduced in the MTP-NRP1 
treated group compared to the vehicle receiving group. 
This demonstrated the anti-tumor effect of MTP-NRP1 in 
a syngenic model.
MTP-NRP1 inhibits proliferation of human 
breast cancer cells
To address the biological activity of MTP-
NRP1 on human breast cancer cells we next performed 
Figure 1: MTP-NRP1 inhibits breast tumor cell proliferation. A. Expression of NRP1 in murine 4T1 cell line. B. MTT assay 
demonstrating the in vitro anti-proliferative activity of MTP-NRP1 peptide. C. Size of 4T1-derived subcutaneous tumors after 3 weeks 
every 3 days IP administration of MTP-NRP1 determined with bioluminescence. (* p < 0.05, Mann Whitney test). D. Expression of NRP1 
and anti-proliferative activity of MTP-NRP1 on human MCF7 breast cancer cells. E. Expression of NRP1 and anti-proliferative activity of 
MTP-NRP1 on human SKBR3 breast cancer cells. F. Expression of NRP1 and anti-proliferative activity of MTP-NRP1 on human MDA-
MB231 breast cancer cells. (ns: not significant, ** p < 0.01 and *** p < 0.001, Mann Whitney test).
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a proliferation MTT assay on three different NRP1 
expressing cell lines, MCF7, SKBR3 and MDA-MB231 
(see Figure 1D-1F showing the expression at protein 
level). Q-RTPCR analysis confirmed the expression of 
NRP1 and showed similar amounts of mRNA for all cell 
lines (see Supplementary Figure S1). Cells were treated 
with increasing doses of MTP-NRP1 ranging from 10-8M 
to 10-6M for 24 hours. MTP-NRP1 induced a significant 
reduction of cell numbers as from 10-8M in MDA-MB231 
(-11% up to -89% at 10-6M), 10-7M in MCF7 cells (-12% 
up to -90% at 10-6M) and 10-6M in SKBR3 (-12%). Higher 
concentrations were not possible to test because of a non-
specific toxicity of the vehicle. Because the triple negative 
MDA-MB231 cells are highly metastatic and represent 
an important therapeutic challenge we decided to focus 
on this cell line for in vivo experiments. Strikingly, the 
addition of MTP-NRP1 (10-6M) fully blocked the Sema3A-
induced phosphorylation of AKT (Figure 2). Because of 
the important role of AKT in the metastatic process this 
result strengthened the need to investigate the therapeutic 
potential of MTP-NRP1 in vivo. Considering reported 
cases of toxicity with anti-NRP1 antibodies we decided 
to use the 10-7 M as a compromise between efficacy and 
low risk of toxicity. While not producing the maximal 
anti-proliferative effect in vitro, this concentration was 
indeed previously proven efficient and safe when treating 
brain tumors [13]. Hence, we monitored tumor growth 
by bioluminescence quantification at week 2, 5, 9 and 13 
upon injection of luciferase expressing MDA-MB-231 
by a life imaging system (NightOwl, Berthold). Initial 
experimental conditions were standardized by establishing 
groups of similar cumulated bioluminescence two weeks 
after grafting of 106 cells in the mouse mammary fat pad 
(average bioluminescence in the vehicle group being 
4147 cps and 4189 cps in the MTP-NRP1 group (p = 
0.9, Mann Whitney). Mice were treated three times a 
week by intra-peritoneal injection of either the vehicle 
(LDS, 72 μM) or MTP-NRP1 (10-7M). A total number of 
12 animals composed each group. Figure 2A is showing 
representative examples of the orthotopic tumors detected 
in the control and the MTP-NRP1 treated groups over 
time. To analyze extensively the response of each mouse 
to the treatment a waterfall plot of best response was 
applied by using the bioluminescence increase between 
week 9 and 13. This analysis revealed that 100% of the 
MTP-NRP1 treated animals responded to the treatment 
with 25% of SD (Stable Disease, < -30% growth decrease 
compared to averaged growth of control tumors) and 
75% responded with PR (Partial Response >-30% growth 
decrease compared to averaged growth of control tumors) 
including two individuals above or equal to 90% decrease 
of tumor volume expansion (Figure 2B). This part of the 
Figure 2: MTP-NRP1 inhibits Sema3A-induced phospho-AKT.A. Representative western blots showing the induction of 
AKT phosphorylation upon treatments with 200ng/ml Sema3A and with or without MTP-NRP1. Akt and p-AKT expression levels were 
normalized with GAPDH. B. Quantitative analysis of 3 independent experiments showing the relative expression of p-AKT/AKT in the 
different experimental conditions. (*= p<0.05, ns: not significant; Mann Whitney test).
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study demonstrated that blocking NRP1 in triple-negative 
breast tumors significantly blocks tumor growth in all 
treated mice.
The duration of our protocol was not sufficient to 
detect metastasis in any organs at bioluminescence or 
histological level. Therefore, we applied a more sensitive 
approach by measuring the human specific mRNA coding 
for the human specific HBMS housekeeping gene and 
compared expression to the corresponding mouse specific 
HBMS gene transcript in vehicle or MTP-NRP1 treated 
mice. This approach allowed us to detect lung metastases 
in the vehicle group, yet not in other organs such as 
the brain (Figure 3). Strikingly, we found that MTP-
NRP1 significantly reduced lung metastasis issued from 
the primary tumor almost to background level. Due to 
insufficient production of metastases we decided to use 
a different model to evaluate the anti-metastatic effect of 
MTP-NRP1.
MTP-NRP1 exhibits anti-metastatic properties
The occurrence of lung metastasis is a crucial 
step in breast cancer progression and is linked to the 
disease-associated death [17]. Thus, we decided to 
monitor whether MTP-NRP1 would impede breast 
cancer metastasis development and progression. 
Figure 3: MTP-NRP1 inhibits primary breast tumor growth in vivo. A. Representative examples of the orthotopic tumors 
(MDA-MB231 cells) detected in the control or the MTP-NRP1 group treated with 1 μg/kg three times a week over time (2, 5, 9 and 13 
weeks). B. Demonstration of the inhibitory effect of MTP-NRP1 on primary tumor growth between week 9 and 13 of treatment. The 
Waterfall graph represents the percent change in tumor volume of individual treated animals (grey and white bars, n=12) compared to the 
averaged tumor volume increased determined in the control group (dark bar, n=12). This demonstrates that 100% of the treated animals 
responded to MTP-NRP1 treatment including 25% with stable disease (SD grey bars) and 75% with partial response (PR white bars). 
SD (Stable Disease, < -30% growth decrease compared to averaged growth of control tumors), PR (Partial Response > -30% growth 
decrease compared to averaged growth of control tumors) (C) RT-QPCR analysis of human specific HMBS mRNA content in the lung to 
reflect metastasis colonization. Results are mRNA quantity compared to the corresponding mouse specific HMBS housekeeping gene and 
expressed as 2(-CT_Hs_HBMS/CT_Ms_HBMS). Statistical analysis was done by comparing mRNA content with background signal determined in the 
lung of control mice without primary tumors (ns= not significant, ** p < 0.01, Mann Whitney test). (D) Similar analysis was conducted in 
the brain. However, no significant human specific HMBS signal was detected in this organ.
Oncotarget5www.impactjournals.com/oncotarget
Mice were here again treated with 1.5 μg/kg of MTP-
NRP1 or with the vehicle (LDS, 72μM). Treatment was 
started 2 days post-intracardiac grafting of 105 MDA-
MB231 cells in the left ventricle. Figure 4A is exhibiting 
representative examples of mice developing metastases 
over time in the two experimental groups. The location 
of metastasis was confirmed at histological level in 
pilot studies to validate accuracy of the method (see 
Supplementary Figure S2). Strikingly, the quantification 
of the cumulated bioluminescent signal showed that 
MTP-NRP1 dramatically reduced the number (-62%, 
Figure 4C) and size (-83%, Figure 4B) of the arising 
metastases. Noteworthy, when further addressing the 
sites of metastasis (in the lung, bone and brain, the major 
metastatic sites in human breast cancer) we found that 
the number of metastasis decreased significantly in all 
analyzed sites upon treatment with MTP-NRP1 (Figure 
4D–4G).
MTP-NRP1 improves overall survival
To finally address the therapeutic benefit of 
MTP-NRP1 we also monitored overall survival (OS) 
of mice during the whole protocol. Consistently, the 
high response rate of mice to MTP-NRP1, both in 
terms of reduced primary tumor volume and number of 
metastasis, translated into a significant survival benefit 
(+ 24.7% of the mean survival, p = 0.0109 compared 
to vehicle, Log-ranked test), a survival benefit also 
exemplified by a 41.5% increase of the median survival 
(Figure 5). It is important to note that this protocol lasted 
for 92 days during which only 16% of the mice died in 
the MTP-NRP1 group while death reached 58% in the 
control group. This long term three weekly injection 
mimicking chronic application provided the possibility to 
evaluate a potential toxicity of MTP-NRP1 arising after 
longer term treatment. Blood samples were collected 
Figure 4: MTP-NRP1 exhibits anti-metastatic properties. A. Representative examples of the metastases (MDA-MB231 cells) 
detected in the vehicle and MTP-NRP1 treated groups over time (4, 6, 8, 10, 12 and 13 weeks). B. Cumulated bioluminescence signal 
obtained in vehicle (control) and MTP-NRP1 treated groups over time. C. Cumulated number of metastases in entire animals over time. 
Detailed analysis of cumulated number of metastasis in lung D., bone E., brain F. and other sites G. in control and MTP-NRP1 treated 
animals. (*** p < 0.001, Extra sum-of-squares F test).
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from the cardiac cavity for analysis before sacrifice 
of animals of both the orthotopic and the systemic 
metastasis model. In all cases, MTP-NRP1 did not 
worsen biological parameters of mice including renal, 
hepatic and cardiac markers. A seen in Supplementary 
Table S1 and S2, we rather observed a significant lower 
level of Lactate Dehydrogenase (LDH) reflecting better 
function of organs in the treated group. Interestingly, the 
level of platelets was significantly lower in the control 
group compared to MTP-NRP1 treated mice. Because a 
transient reduction of platelets in patients treated with 
an anti-NRP1 antibody was one of the most common 
(67% of the patients) reported adverse effect in a phase 1 
clinical study, this result further demonstrated the good 
body tolerance for MTP-NRP1.
MTP-NRP1 treatment prevents metastasis 
formation
The anti-metastatic effect of MTP-NRP1 on 
primary tumors and induced lung metastases together 
with the good tolerance of the peptide prompted us to 
test whether protective treatment of mice by the peptide 
before grafting the tumor cells potentially was beneficial. 
We produced metastases by engrafting MDA-MB231 
cells through intra-cardiac injections after 3 days of 
continuous pre-medication of mice with MTP-NRP1 or 
by pre-incubating the tumor cells with the peptide 1h 
before engraftment. We found that both pre-treatments 
strongly reduced the occurrence of metastases by roughly 
60% when determined 3 weeks post grafting (Figure 5B). 
Figure 5: MTP-NRP1 improves overall survival and exhibits protective effect against metastasis. A. Kaplan Meyer 
survival curve demonstrating a significant increased survival of the treated MTP-NRP1 animals compared to the control animals. (* p < 
0.05, Log Rank test). B. Total number of metastases determined in animals that had received IP administration of MTP-NRP1 for 3 days 
before intracardiac grafting (“pre-medication”) or that were grafted with cells (all MDA-MB231) pre-incubated with the peptide (“in 
cells”). C. Averaged intensity of bioluminescence (cps) emitted by metastases that were able to grow in the different experimental groups. 
(ns= not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, Mann Whitney test).
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This result suggested that blocking NRP1 is able to 
reduce metastatic colonization. Over the 3 weeks period 
of survey, the few metastases that had developed in mice 
receiving premedication were growing similarly well as 
the control group (Figure 5C). However, those metastases 
originating from cells that had been pre-incubated with the 
MTP-NRP1 peptide were 95% smaller (p=0.0006 Mann 
Whitney test, Figure 5C). These results demonstrated 
that pre-medication has a beneficial impact on metastasis 
development and growth. In addition, our results clearly 
demonstrated a NRP1 cell autonomous metastatic 
mechanism.
DISCUSSION
The action mechanism of MTP-NRP1 has been 
well documented and is known to mainly relate to the 
interference of receptor dimerization [13, 14, 18, 19]. 
Here, we have shown an anti-proliferative property of 
MTP-NRP1 in one murine cell line and three different 
human breast cancer cell lines. The efficacy was 
stronger in MCF7 and MDA-MB231 but modest in 
SKBR3 cells. This milder effect in SKBR3 may be due 
to the overexpression of HER2 providing a dominant 
pathway for cell proliferation [20]. Nonetheless, MTP-
NRP1 appeared as a very potent inhibitor of primary 
breast tumor growth generated with 4T1 cells grafted 
in immunocompetent Balb/C mice. The demonstration 
of the clinical potential of MTP-NRP1 was confirmed 
by producing orthotopic breast tumors in nude mice 
grafted with human MDA-MB231 cells in the mammary 
fat pad. When using objective individual tumor growth 
parameters adapted from the RECIST criteria [15, 16], 
we found that 100% of mice responded to the treatment. 
Furthermore, MTP-NRP1 induced a significant decrease 
of lung metastasis arising from the primary tumors. This 
anti-metastatic effect was further explored in the intra-
cardiac grafting assay that showed both a reduction in the 
number and in the size of metastasis in all three major 
sites observed in human, the bone, lung and brain. The 
anti-tumor effect is obtained with a very low dosage 
of 1 μg/kg of MTP-NRP1. This is in accordance with 
our previous work that showed successful inhibition 
of glioma growth in vivo with the same concentration 
of MTP-NRP1. However, in the case of breast cancer 
cells, the maximal effect was obtained in vitro with 10-
6M, a concentration similar to the one employed for 
MTP-NeuNT peptide targeting the TMD of the NeuNT 
receptor [21]. Based on our results future studies can 
be launched to further explore other parameters such as 
higher MTP-NRP1 concentrations to reach the maximal 
anti-tumor effects (optimal dosage, maximum tolerated 
dose), best therapeutic scheme (duration of treatment, 
therapeutic window) and potential combinations with 
other anti-breast cancer drugs. Future PK/PD analyses 
are necessary that currently are not yet possible due to the 
lack of tools to detect and measure hydrophobic peptides. 
Importantly, based on blood analysis after the long period 
of treatment (13 weeks), the MTP-NRP1 peptide did not 
show any toxicity. Although we did not reach the maximal 
tolerated dose here, similar experiments had been done 
in the glioblastoma model where no toxicity was seen 
in any tested organ. Noteworthy, no cutaneous lesions 
were observed on all mice around the intra-peritoneal 
injection site of the drug. This suggested the lack of 
peptide accumulation at the injection site avoiding a risk 
of local toxic side effect. A phase I study of the human 
monoclonal anti-NRP1 antibody MNRP11685A showed 
good tolerance when administrated as a single agent [22]. 
This study only reported cases of transient platelet count 
reductions without severe impact. We did not observed 
such a phenomenon in our study thereby suggesting that 
MTP-NRP1 is extremely well tolerated with the low yet 
effective dosage we used. It will be interesting to further 
evaluate the tolerance in future studies dedicated to the 
identification of the best dosage in stand alone or in 
combination with other drugs.
Finally, pre-medication using MTP-NRP1 showed 
a clear reduction of metastasis occurrence/appearance. 
When administrating the peptide to the mice before 
grafting tumor cells, the number of metastatic events 
dropped suggesting that the seeding capacity of the cells 
is affected when blocking NRP1 in the microenvironment. 
However, this pretreatment was inefficient on cells that 
had succeeded extravasation from the blood stream. 
The cells were able to soil [23] and develop metastases 
demonstrating that the pre-medication preferentially 
impacted on tumor cells before breaching blood vessels 
to enter the lung parenchymal tissue. When the cells were 
pre-incubated with the peptide, thereby blocking NRP1 
cell–autonomous signaling pathways, we found both 
a reduction of the number and size of metastases. This 
illustrates that NRP1 is involved in both cell autonomous 
and non-cell-autonomous mechanisms controlling the 
metastatic process.
Targeting the TMD of bitopic receptors such as 
NRP1 provides a new exquisite therapeutic tool. Previous 
work demonstrated a crucial role of the TMD of NRP1 
and suggested that inhibition may present a therapeutic 
potential in glioma treatment [13, 14]. This strategy has 
been now validated for another type of cancer, breast 
cancer and its related metastases. Our results clearly 
revealed that a peptide mimicking the TMD of NRP1 
decreases both the size and the number of breast metastasis 
translating into a marked improvement of survival. 
Importantly, this therapeutic benefit was achieved by using 
the drug in a micromolar dosage with no apparent toxicity. 
Hence, targeting the TMD of NRP1, with a peptide 
mimicking its TMD could be a future potent drug in breast 
cancer therapy particularly to prevent metastasis formation 
by administrating long term low dose MTP-NRP1 upon 
reduction or surgical removal of the primary tumor.
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MATERIALS AND METHODS
Cell culture
The murine 4T1 cells and human epithelial breast 
adenocarcinoma derived from pleural effusion MDA-
MB-231 (ER-, PR-, HER2-), MCF7 (ER+, PR+, HER2+), 
SKBR3 (ER-, PR-, HER2+) cells were grown in Dulbecco’s 
modified Eagle medium (DMEM, GIBCO) and HUVEC 
(Human Umbilical Vein Endothelial Cells, Promo Cell) cells 
were cultured in Endothelial Cell Growth Medium (Promo 
Cell). MDA-MB-231 cells were purchased from ECACC 
(92020424), HUVEC cells were purchased from Promo Cell 
(C-12200), MCF7 and SKBR3 cells were obtained from our 
institute collection. All culture media were supplemented 
with 10% fetal calf serum (FCS) (Gibco), 100 I.U./ml 
penicillin, 100 μg/ml streptomycin (Sigma), and cultured 
at 37°C, 5% CO2. Cells were detached with trypsin-EDTA 
(0.05 % trypsin, 1X EDTA), spin down and split regularly up 
to 40 passages before new stocks were thawed.
Peptides
Peptides have been synthesized by Peptide Specialty 
Laboratories GmbH using automatic peptide synthesis (Fmoc 
chemistry). The peptide corresponding to the TM sequence of 
NRP1: ILITIIAMSALGVLLGAVCGVVLYRKR is referred 
as MTP-NRP1. Peptides purity estimated by RP-HPLC 
was more than 95% according to manufacturer indication. 
Peptides were solubilized in LDS (Lithium Dodecyl Sulphate, 
72 mM for stock solution) as previously described [13, 14].
RTQ-QPCR
mRNA was extracted with TriReagent solution 
according to manufacturer’s instruction (Molecular 
Research Center Inc., Euromedex). mRNA was treated 
with DNaseI (Invitrogen) and reverse transcribed using 
the High Capacity cDNA RT Kit (Life Technologies). 
Quantitative reverse transcriptase polymerase chain 
reaction (RTQ-PCR) was performed using the Power 
SYBR Green PCR Master Mix or TaqMan Gene 
Expression Master Mix (Life Technologies) using 
the 7500 Real time PCR System (Life Technologies) 
following the manufacturer’s protocol. We used human 
specific Hs_HMBS (QT 00014462, Quiagen) and mouse 
specific Ms_HBMS (QT00494130, Quiagen) to quantify 
lung or brain metastasis contents. Samples were analyzed 
using 2μl cDNA. Calculation were effectuated as the 
following: Δct(MDA-MB-231HBMS) = ct (Hs_HBMS) – ct 
(Ms_HBMS), mRNA quantity = 2(-ΔctMDA-MB-231HBMS).
Western blot analysis
MDA-MB 231 cells were seeded on 6-well plates 
overnight, and then treated with 200ng/ml Sema3A 
(R&D 1250-S3) for 30 minutes prior to addition of 
10-6M of MTP-NRP1 for one additional hour. Proteins 
were extracted in Laemmli buffer complemented with 
proteinases (Roche, #11836145001) and phosphatases 
(5mM of Na ortho-vanadate) inhibitors. They were 
loaded on a 4-15% gradient gel (Biorad). Antibodies 
for Akt, phospho Akt (Cell Signaling #4060 and 
#9272 respectively), GAPDH (Santa Cruz #SC-20357) 
and their respective rabbit and goat–HRP secondary 
antibodies (GE Healthcare) were used. Revelation was 
performed using Pierce™ ECL Plus Western Blotting 
Substrate and the PXi imager apparatus (Syngene Bio 
Imaging, UK). Quantification was done with image j 
software.
Immunocytochemistry
Cells were grown on sterile glass cover slips for 
one day before immunofluorescence staining. The cells 
were fixed with freshly made fixative 4% formaldehyde 
(FA) for 10 minutes. The samples were gently rinsed 
with PBS (1 wash for 10 minutes) before adding fetal 
calf serum blocking solution (FCS 5%) for a minimum 
of 30 minutes. Cells were permeabilized using 1x PBS 
with 0.1% Tween20 for 5 minutes. Anti-neuropilin-1 (sc-
5541; Santa Cruz Biotechnology) diluted in 5% FCS-PBS 
was added to the cell over night at room temperature. 
After thorough wash (3 washes of 5 minutes) appropriate 
secondary antibody (goat anti-rabbit, Nordic Immunology 
GAM/Fab/TRITC diluted 1/1000 from stock) was added 
at room temperature for 90 minutes. After washing in PBS, 
the cell nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole, 1/30 000 in water) for 10 minutes. Glass 
coverslips were finally mounted on microscopy glass 
slides using a polymerization medium (FluorSave reagent, 
Calbiochem-Merck, cat#345789).
Cell proliferation
In vitro cell proliferation was monitored using MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) proliferation assay according to manufacturer’s 
instruction (Sigma, M2128, USA). Cells were seeded at a 
density of 10 000 cells per well in a 96 well plate before 
incubation with increasing peptide concentration (ranging 
from 10-9M to 10-6M) or corresponding vehicle increasing 
concentration (LDS, ranging from 0.72 μM to 720 μM). 
After 24h incubation, the culture media were removed 
from the wells and 100 μl of MTT dye freshly diluted 
(to 1/50 in GBSS) from stock solution (5 mg/ml) was 
added to each well for 4h. After this incubation period, 
isopropanol (100 μl) was added to the MTT solution in 
each well before reading the optical density at 570 nm 
using a microplate reader spectrophotometer (EL800, 
Bio Tek Instruments). For cell fluorescence acquisition, 
images were acquired with the fluorescence Zeiss Imager 
Z2 equipped with HXP 120W lamp and structured light 
ApoTome (Zeiss) system
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Orthotopic grafting of cells in the mouse 
mammary fat pad
Nude mice (8 weeks of age) were anesthetized 
(Initially 3% isoflurane with air/O2 mix, then animals were 
kept under anaesthesia with 1.5% Isoflurane with air/O2 
mix). A cutaneous incision up to the sternum was completed, 
followed by another angled lateral incision from the initial 
one towards the posterior leg. The blood vessel emerging 
between these fat pads was cauterised (Electric cauterizer 
(FST No 18000-00). Then the needle (BD Microlance; 22G ¼ 
- Nr 12; 0,7 x 30 mm, REF 300900) of the syringe containing 
106 cells in 50μl of PBS was inserted in the mammary fat 
pad from the external side up to the lymph node and the cells 
were injected behind the lymph node within the mammary 
fat pad. Skins were then aligned and sutured. The mouse was 
monitored until it was awakened from the procedure and was 
moving around the cage normally and then observed on a 
daily basis until sacrifice. For bioluminescence detection, 
IP injection of 100μl of a luciferin solution at 30mg/ml was 
completed on a weekly basis for each mouse. Acquisition 
was operated for 5min using a live imager (NightOwl, 
Berthold). All treatments were administrated by IP injection 
of 100μl solutions containing 72μM LDS (control group) or 
1 μg/kg MTP-NRP1. Injections were performed every 3 days 
once the tumors reached a volume of 200 mm3. The percent 
change in bioluminescence intensity at week 9 and 13 was 
used to quantify response. PD (Progression disease, >20% 
increase compared to averaged growth of control tumors), 
SD (Stable Disease, < -30% growth decrease compared to 
averaged growth of control tumors), PR (Partial Response 
> -30% growth decrease compared to averaged growth of 
control tumors), and CR (Complete response, 100% growth 
decrease compared to averaged growth of control tumors) 
were defined as per RECIST criteria.
Intra-cardiac grafting model
Cells were detached with Versene (EDTA solution 
used in order to assess a gentle non-enzymatic cell 
dissociation), washed and counted for 105 in 100μl of PBS 
before injection into the left ventricle of nude mice (8 
weeks old) using a 26G ½ needle with a 1ml syringe. Mice 
were initially anesthetized with 3% isoflurane with air/O2 
mix and animals were kept under anaesthesia with 1.5% 
isoflurane with air/O2 mix during surgery). Monitoring 
procedure and bioluminescence detection were identical 
to above described orthotopic injection.
Animal handling and in vivo ethical statement
Experiments were performed according to the 
Guide for Care and Use of Laboratory Animals (E67-6-
482-21) and the European Directive with approval of the 
regional ethical committee (Reference AL/55/62/02/13). 
Mice received food and water ad libitum. Animals were 
sacrificed using CO2. All necessary precautions were 
taken to minimize pain or discomfort of the animals. 
General health status was monitored 3 times a week 
by independent observers. Mice were sacrificed when 
reaching ethical endpoints.
Statistics
Statistical analyses were performed using Mann 
Whitney test (for sample n < 30), Log ranked test 
for survival analysis and sum-of-squares F test using 
GraphPad software (Prism, USA). P-values are given in 
the figure legends, and values of P < 0.05 were considered 
to be statistically significant. Normal distribution of the 
values was checked using GraphPad software (Prism, 
USA). A minimum of three independent experiments 
including at least triplicates was performed for in vitro 
proliferation assay. For in vivo experiment sample size 
calculation anticipated a therapeutic effect of 20% for 
a standard deviation of 14% and confidence interval of 
confidence 95% (Lamorte’s Power calculation, University 
of Boston). Results from two independent in vivo 
experiments were pooled only if fully comparable (no 
statistical differences between control groups).
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